FDA Approves Genentech's Enspryng for Thyroid Eye Disease

The US Food and Drug Administration has approved Genentech's Enspryng (satralizumab-mwge) for adults with thyroid eye disease, the Roche company said on October 15. Genentech says it is the first treatment for the condition that patients or caregivers can inject at home, after training from a health care provider.

What happened

Enspryng is an antibody that blocks the interleukin-6 receptor (IL-6R). Genentech calls it a first-in-class IL-6R inhibitor. It is given as a subcutaneous injection every four weeks in the maintenance phase.

The approval rests on the phase 3 SatraGO program. It had two randomized, placebo-controlled trials that together enrolled 258 patients in 19 countries. The main goal was a drop in eye bulging (proptosis) of at least 2 mm at week 24.

• SatraGO-2: in patients with active disease, 52.9% on Enspryng had a proptosis response, compared with 23.4% on placebo. Double vision improved in 60.7% versus 25.8%.
• SatraGO-1: this trial did not meet its pre-specified primary endpoint at week 24.

Genentech said the trials found no new safety signals. The company said the profile matched what is known from the drug's use in neuromyelitis optica spectrum disorder (NMOSD).

The FDA reviewed the application under priority review. This is the drug's second US indication. It was first approved for NMOSD in 2020.

Why it matters

Thyroid eye disease is progressive, and the trials measured two of its effects: eye bulging and double vision. Genentech says it affects about 155 people per 100,000 in the US.

The market already has two approved treatments. Healio reports that Enspryng is the third FDA-approved option, alongside Amgen's Tepezza and Viridian's Lumvoa. A University of Pennsylvania ophthalmologist quoted by Genentech said a subcutaneous option could ease the logistics that come with infusion-based care.

The evidence is mixed. One of the two phase 3 trials missed its main goal, while the other showed clear gains over placebo.

What it means for people in the industry

Genentech did not announce new jobs or sites tied to this approval. For now, the story is about competition among treatments for this condition.

• Watch for US launch and patient support plans, since home use requires training from a health care provider.
• Watch how the price and payer coverage compare with the infusion products already on the market.
• Genentech also has an FDA decision due in January 2027 for Enspryng in MOG antibody disease (MOGAD).

This article is news, not medical advice. Patients should talk to their own care team about treatment.

More pharma and biotech news

Sources

• FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED), Genentech
• FDA approves Enspryng for thyroid eye disease, Healio